Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if omalizumab co-treatment may allow reintroduction
of honey bee venom immunotherapy in patients with immunotherapy treatment failure due to
systemic reactions.
Phase:
N/A
Details
Lead Sponsor:
The University Clinic of Pulmonary and Allergic Diseases Golnik